Reoperation in metastasizing medullary thyroid carcinoma: Is a tumor stage-oriented approach justified?☆
References (23)
- et al.
Advances in the diagnosis and treatment of medullary thyroid carcinoma
Surg Clin North Am
(1987) - et al.
Medullary thyroid carcinoma: relationship of method of diagnosis to pathologic staging
Ann Surg
(1978) - et al.
Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma
Ann Surg
(1990) - et al.
Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma
Jpn J Surg
(1994) - et al.
Medullary carcinoma of the thyroid: a study of clinical features and prognostic factors in 161 patients
Medicine
(1984) - et al.
Prognostic factors in medullary thyroid carcinomas: survival in relation to age, sex, histology, immunocytochemistry, and DNA content
Cancer
(1988) - et al.
Radioactive iodine in the treatment of medullary thyroid carcinoma of the thyroid
J Clin Endocrinol Metab
(1983) - et al.
Kombinationstherapie von Adriamycin, Cisplatin und Vindesin beim C-Zell-Carcinom der Schilddrüse
Onkologie
(1990) - et al.
Therapie des metastasierten medullären Schilddrüsenkarzinoms mit dem Somatostatinanalogon Octreotide
Med Klin
(1995) - et al.
Medullary carcinoma of the thyroid: therapeutic strategy derived from fifteen years of experience
Surgery
(1993)
Surgical management and follow-up of medullary thyroid carcinoma
J Surg Oncol
Cited by (58)
Multiple Endocrine Neoplasia
2011, Williams Textbook of Endocrinology, Twelfth EditionThe surgical management of medullary thyroid cancer
2010, Otolaryngologic Clinics of North AmericaCitation Excerpt :The goal of lymphadenectomy for asymptomatic calcitonin elevations is the removal of microscopic metastatic nodal disease to prevent dissemination.7 However, a number of case series have shown that only a minority of patients actually achieve a biochemical cure following reoperative regional lymphadenectomy.9,11,12,21,22 In a recent series from Moley and colleagues,22 an improved ability to normalize postoperative serum calcitonin levels was found compared with an earlier series.21
Medullary Thyroid Carcinoma and Multiple Endocrine Neoplasia Type 2
2010, Endocrinology: Adult and Pediatric, Sixth EditionSurgical approaches in thyroid cancer and lymph-node metastases
2008, Best Practice and Research: Clinical Endocrinology and MetabolismCitation Excerpt :For the adequate planning of many reoperations, this information can be critical, sparing patients with occult MTC an odyssey through myriad institutions with continual imaging and further unnecessary operations. With the advent of the compartment-oriented microdissection technique, reoperations for MTC have become more effective in normalizing calcitonin levels.55,110–112 Suggestive of cure in the absence of distant metastases, the concept of biochemical normalization has gained much popularity as a key performance indicator against which the adequacy of the operation is gauged.
Outcomes in Reoperative Thyroid Cancer
2008, Otolaryngologic Clinics of North AmericaCitation Excerpt :Surgeon philosophy in level of aggressiveness seems to influence the frequency of complications. Gimm and Dralle [16] report on 36 consecutive patients undergoing reoperation for MTC. The indication for reoperation in all patients was elevated calcitonin, with most patients also having imaging evidence of residual or recurrent regional disease.
Contralateral cervical and mediastinal lymph node metastasis in medullary thyroid cancer: Systemic disease?
2006, SurgeryCitation Excerpt :In symptomatic patients, however, medullary thyroid cancers frequently are node-positive and more advanced. Clearance of lymph node metastases by systematic dissection may afford local control in the neck3,4-6,10,15-19 and mediastinum20 and may prevent tracheal and esophageal invasion owing to tumor penetration of the lymph node capsule.21 From a surgical perspective, it is important to distinguish between local disease, which may be surgically curable, and systemic disease, in which palliation is the ultimate goal of therapy.
- ☆
Presented at the Eighteenth Annual Meeting of the American Association of Endocrine Surgeons, Baltimore, Md., April 6–8, 1997.